NCT06018116View on ClinicalTrials.gov

A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 7, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

February 12, 2024

Conditions

Metastatic Urothelial Carcinoma

Interventions

DRUG

Bicalutamide 150 mg

nonsteroidal antiandrogen

DRUG

Placebo

placebo

Trial Locations (1)

G1G 5X1

CHU de Québec - Université Laval, Québec

Sponsors

Collaborators (1)

Cancer Research Society

All Listed Sponsors

collaborator

Cancer Research Society

OTHER

lead

CHU de Quebec-Universite Laval

OTHER

NCT06018116 - A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer. | Biotech Hunter | Biotech Hunter